drugset / Trial / NCT01284868

A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.

NCT01284868

Phase 1 Completed 12 enrolled Astellas Pharma Inc
RandomizedCrossoverSingle-blindBasic science

Summary

To explore what is driving heart-rate increases after dosing with mirabegron. Subjects will be given a beta-blocker at the same time as mirabegron.

Timeline

Start
2009-07
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Bisoprolol Other / unclassified Oral
Subject Mirabegron Other / unclassified Oral
Subject Propranolol Small molecule Oral

Indications

No indication recorded.